228 related articles for article (PubMed ID: 32985652)
1. NEWTON-2 Cisternal (Nimodipine Microparticles to Enhance Recovery While Reducing Toxicity After Subarachnoid Hemorrhage): A Phase 2, Multicenter, Randomized, Open-Label Safety Study of Intracisternal EG-1962 in Aneurysmal Subarachnoid Hemorrhage.
Macdonald RL; Hänggi D; Ko NU; Darsaut TE; Carlson AP; Wong GK; Etminan N; Mayer SA; Aldrich EF; Diringer MN; Ng D; Strange P; Bleck T; Grubb R; Suarez JI
Neurosurgery; 2020 Dec; 88(1):E13-E26. PubMed ID: 32985652
[TBL] [Abstract][Full Text] [Related]
2. Clinical Trial Protocol: Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study Comparing EG-1962 to Standard of Care Oral Nimodipine in Adults with Aneurysmal Subarachnoid Hemorrhage [NEWTON-2 (Nimodipine Microparticles to Enhance Recovery While Reducing TOxicity After SubarachNoid Hemorrhage)].
Hänggi D; Etminan N; Mayer SA; Aldrich EF; Diringer MN; Schmutzhard E; Faleck HJ; Ng D; Saville BR; Macdonald RL;
Neurocrit Care; 2019 Feb; 30(1):88-97. PubMed ID: 30014184
[TBL] [Abstract][Full Text] [Related]
3. NEWTON: Nimodipine Microparticles to Enhance Recovery While Reducing Toxicity After Subarachnoid Hemorrhage.
Hänggi D; Etminan N; Macdonald RL; Steiger HJ; Mayer SA; Aldrich F; Diringer MN; Hoh BL; Mocco J; Strange P; Faleck HJ; Miller M
Neurocrit Care; 2015 Oct; 23(2):274-84. PubMed ID: 25678453
[TBL] [Abstract][Full Text] [Related]
4. Randomized, Open-Label, Phase 1/2a Study to Determine the Maximum Tolerated Dose of Intraventricular Sustained Release Nimodipine for Subarachnoid Hemorrhage (NEWTON [Nimodipine Microparticles to Enhance Recovery While Reducing Toxicity After Subarachnoid Hemorrhage]).
Hänggi D; Etminan N; Aldrich F; Steiger HJ; Mayer SA; Diringer MN; Hoh BL; Mocco J; Faleck HJ; Macdonald RL;
Stroke; 2017 Jan; 48(1):145-151. PubMed ID: 27932607
[TBL] [Abstract][Full Text] [Related]
5. Single-Dose Intraventricular Nimodipine Microparticles Versus Oral Nimodipine for Aneurysmal Subarachnoid Hemorrhage.
Carlson AP; Hänggi D; Wong GK; Etminan N; Mayer SA; Aldrich F; Diringer MN; Schmutzhard E; Faleck HJ; Ng D; Saville BR; Bleck T; Grubb R; Miller M; Suarez JI; Proskin HM; Macdonald RL;
Stroke; 2020 Apr; 51(4):1142-1149. PubMed ID: 32138631
[TBL] [Abstract][Full Text] [Related]
6. Intravenous magnesium versus nimodipine in the treatment of patients with aneurysmal subarachnoid hemorrhage: a randomized study.
Schmid-Elsaesser R; Kunz M; Zausinger S; Prueckner S; Briegel J; Steiger HJ
Neurosurgery; 2006 Jun; 58(6):1054-65; discussion 1054-65. PubMed ID: 16723884
[TBL] [Abstract][Full Text] [Related]
7. Stereotactic cisternal lavage in patients with aneurysmal subarachnoid hemorrhage with urokinase and nimodipine for the prevention of secondary brain injury (SPLASH): study protocol for a randomized controlled trial.
Roelz R; Schubach F; Coenen VA; Jenkner C; Scheiwe C; Grauvogel J; Niesen WD; Urbach H; Taschner C; Seufert J; Kätzler J; Beck J; Reinacher PC
Trials; 2021 Apr; 22(1):285. PubMed ID: 33858493
[TBL] [Abstract][Full Text] [Related]
8. Intrathecal application of the nimodipine slow-release microparticle system eg-1962 for prevention of delayed cerebral ischemia and improvement of outcome after aneurysmal subarachnoid hemorrhage.
Etminan N; Macdonald RL; Davis C; Burton K; Steiger HJ; Hänggi D
Acta Neurochir Suppl; 2015; 120():281-6. PubMed ID: 25366637
[TBL] [Abstract][Full Text] [Related]
9. A Site-Specific, Sustained-Release Drug Delivery System for Aneurysmal Subarachnoid Hemorrhage.
Hänggi D; Etminan N; Steiger HJ; Johnson M; Peet MM; Tice T; Burton K; Hudson B; Turner M; Stella A; Heshmati P; Davis C; Faleck HJ; Macdonald RL
Neurotherapeutics; 2016 Apr; 13(2):439-49. PubMed ID: 26935204
[TBL] [Abstract][Full Text] [Related]
10. Effect of Locally Delivered Nimodipine Microparticles on Spreading Depolarization in Aneurysmal Subarachnoid Hemorrhage.
Carlson AP; Alchbli A; Hänggi D; Macdonald RL; Shuttleworth CW
Neurocrit Care; 2021 Feb; 34(1):345-349. PubMed ID: 32103439
[TBL] [Abstract][Full Text] [Related]
11. Incidence of Arterial Hypotension in Patients Receiving Peroral or Continuous Intra-arterial Nimodipine After Aneurysmal or Perimesencephalic Subarachnoid Hemorrhage.
Kieninger M; Gruber M; Knott I; Dettmer K; Oefner PJ; Bele S; Wendl C; Tuemmler S; Graf B; Eissnert C
Neurocrit Care; 2019 Aug; 31(1):32-39. PubMed ID: 30725331
[TBL] [Abstract][Full Text] [Related]
12. Intra-arterial nimodipine infusion for cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage.
Cho WS; Kang HS; Kim JE; Kwon OK; Oh CW; Son YJ; Know BJ; Jung C; Hang MH
Interv Neuroradiol; 2011 Jun; 17(2):169-78. PubMed ID: 21696654
[TBL] [Abstract][Full Text] [Related]
13. Molsidomine for the prevention of vasospasm-related delayed ischemic neurological deficits and delayed brain infarction and the improvement of clinical outcome after subarachnoid hemorrhage: a single-center clinical observational study.
Ehlert A; Schmidt C; Wölfer J; Manthei G; Jacobs AH; Brüning R; Heindel W; Ringelstein EB; Stummer W; Pluta RM; Hesselmann V
J Neurosurg; 2016 Jan; 124(1):51-8. PubMed ID: 26162034
[TBL] [Abstract][Full Text] [Related]
14. A multimodal concept in patients after severe aneurysmal subarachnoid hemorrhage: results of a controlled single centre prospective randomized multimodal phase I/II trial on cerebral vasospasm.
Hänggi D; Eicker S; Beseoglu K; Behr J; Turowski B; Steiger HJ
Cent Eur Neurosurg; 2009 May; 70(2):61-7. PubMed ID: 19711257
[TBL] [Abstract][Full Text] [Related]
15. Nimodipine Dose Reductions in the Treatment of Patients with Aneurysmal Subarachnoid Hemorrhage.
Sandow N; Diesing D; Sarrafzadeh A; Vajkoczy P; Wolf S
Neurocrit Care; 2016 Aug; 25(1):29-39. PubMed ID: 26690937
[TBL] [Abstract][Full Text] [Related]
16. The Impact of Nimodipine Administration through Feeding Tube on Outcomes in Patients with Aneurysmal Subarachnoid Hemorrhage.
Isse FA; Abdallah YEH; Mahmoud SH
J Pharm Pharm Sci; 2020; 23(1):100-108. PubMed ID: 32348716
[TBL] [Abstract][Full Text] [Related]
17. Impact of Early Versus Late Intravenous Followed by Oral Nimodipine Treatment on the Occurrence of Delayed Cerebral Ischemia Among Patients With Aneurysm Subarachnoid Hemorrhage.
Samseethong T; Suansanae T; Veerasarn K; Liengudom A; Suthisisang C
Ann Pharmacother; 2018 Nov; 52(11):1061-1069. PubMed ID: 29783859
[TBL] [Abstract][Full Text] [Related]
18. Continuous intra-arterial nimodipine infusion in patients with severe refractory cerebral vasospasm after aneurysmal subarachnoid hemorrhage: a feasibility study and outcome results.
Bele S; Proescholdt MA; Hochreiter A; Schuierer G; Scheitzach J; Wendl C; Kieninger M; Schneiker A; Bründl E; Schödel P; Schebesch KM; Brawanski A
Acta Neurochir (Wien); 2015 Dec; 157(12):2041-50. PubMed ID: 26439105
[TBL] [Abstract][Full Text] [Related]
19. Risks of nimodipine dose reduction during the high-risk period for delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage.
Ditz C; Matone MV; Schwachenwald B; Küchler J
Neurosurg Rev; 2024 Jan; 47(1):37. PubMed ID: 38191859
[TBL] [Abstract][Full Text] [Related]
20. Letter by Rustemi Regarding Article, "Randomized, Open-Label, Phase 1/2a Study to Determine the Maximum Tolerated Dose of Intraventricular Sustained Release Nimodipine for Subarachnoid Hemorrhage (NEWTON [Nimodipine Microparticles to Enhance Recovery While Reducing Toxicity After Subarachnoid Hemorrhage])".
Rustemi O
Stroke; 2017 Apr; 48(4):e113. PubMed ID: 28283604
[No Abstract] [Full Text] [Related]
[Next] [New Search]
